1. Pink Sheet
  2. >>Pathways & Standards
  3. >>Approval Standards

OTC Naloxone In US Could Limit Access Due To Costs, Comments On Emergent Switch NDA Argue

 
• By Malcolm Spicer

The American Society of Anesthesiologists and attorney Scott Lassman disagree with the FDA's suggestion that studies showing all naloxone products can be used safely over the counter indicates all of them can be moved to nonprescription status. Both were included in comments submitted ahead of the agency's Nonprescription Drug and Anesthetic and Analgesic Drug Products advisory committee meeting on the subject.

The FDA joint advisory committee will meet on 15 February to discuss Emergent BioSolution's proposed OTC switch of NARCAN. • Source: Shutterstock

Making all naloxone products available OTC in the US could limit, rather than expand, access to the opioid overdose treatment, according to comments submitted before US Food and Drug Administration advisors discuss the first naloxone switch proposal.

The American Society of Anesthesiologists and attorney Scott Lassman both made clear in comments, submitted to the docket for a...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Approval Standards

More from Pathways & Standards

What UK’s Clinical Trials Overhaul Means For Orphan Drug Developers

 
• By Eliza Slawther

The UK government has acknowledged that sponsors of clinical trials for rare diseases face challenges around patient recruitment and trial design, which will be addressed in its clinical trials reform, a lawyer says.

Generic Drug Office’s Policy Staff Returning To US FDA

 
• By Derrick Gingery

The group had been laid off as part of the 1 April reduction-in-force, which led to missed guidance publication deadlines.

Nipah Vaccine With ‘Pandemic Potential’ Wins EMA PRIME Designation

 
• By Neena Brizmohun

The developers of the ChAdOx1 NipahB vaccine will be able to benefit from the early and enhanced support that the European Medicines Agency offers through its priority medicines scheme.